Dr. Ferrer Biopharma to Showcase Groundbreaking Research in Post-COVID Treatment at ERS Congress 2023
6.9.2023 18:17:00 EEST | Business Wire | Press release
Leading pharmaceutical research and development company Dr. Ferrer Biopharma proudly announces its participation in the highly anticipated European Respiratory Society (ERS) Congress 2023 , scheduled in Milan, Italy, from September 9th to 13th. During the event, the company will present late-breaking findings from two randomized controlled trials that shed light on the potential of intranasal Chlorpheniramine to treat post-COVID-19 long-term symptoms.
The ERS Congress serves as a premier platform in respiratory health, featuring the latest advancements in clinical care, scientific research, education, and technology, where experts and researchers worldwide share insights and discoveries, driving progress in respiratory medicine.
Highlighting a pioneering study, the late-breaking abstract by Dr. Ferrer Biopharma introduces Intranasal Chlorpheniramine Maleate (iCPM) as an innovative therapeutic strategy with promising anti-inflammatory and antiviral properties against COVID-19 and respiratory viruses, specifically addressing long-term symptoms. Investigating the effects of this novel approach, Dr. Ferrer Biopharma's presentation delves into the impact of intranasal Chlorpheniramine on post-COVID-19 symptoms, revealing significant improvements in clinical recovery time and alleviation of symptoms like anosmia, ageusia, and cough, as demonstrated by the two randomized trials ACCROS I, and ACCROS III. The subsequent post-trial follow-up highlights Chlorpheniramine's remarkable reduction of post-COVID symptoms by over 90% compared to a placebo.
"The antiviral and anti-inflammatory effect of iCPM can explain the significant impact in reducing time to clinical recovery in the acute illness," said Dr. Franck Rahaghi , Clinical Professor of Medicine and chairman of Cleveland Clinic Florida pulmonary and critical care department, who leads the study. "iCPM may have better impact in reducing long-COVID symptoms. This reformulated treatment could become a cornerstone intervention in addressing the dreaded issue of long-COVID."
"We are excited to unveil the results of our comprehensive research that explores the impact of intranasal chlorpheniramine on post-COVID-19 long-term symptoms," said Dr. Fernando Valerio, Principal Investigator.
The company's participation underscores its dedication to propelling innovation and achieving excellence in respiratory medicine.
About Dr. Ferrer Biopharma:
Dr. Ferrer Biopharma is a pioneering pharmaceutical research and development company dedicated to advancing intranasal medications for treating cough, colds, flu, and allergies. We use advanced technology to bring to the market high-quality, evidence-based, consumer-focused therapies that originated at the bedside.
For more information, please visit DrFerrerBioPharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906892619/en/
Contact information
Daniel Fernández
Marketing Director
+1-954-225-7694
marketing@pulmonary-institute.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBTS and ZIM Connections Bring Travel eSIM to Global Travelers10.2.2026 06:00:00 EET | Press release
SBTS, the joint venture between BTS and SoftBank Corp., and ZIM Connections today announced a strategic partnership to launch a travel eSIM solution, initially focused on inbound and outbound travel into and from Japan. The service is now live and commercially available here, marking the first step in a broader global rollout of multiple travel eSIM offerings. The initial launch is a digital travel eSIM platform developed by ZIM Connections and commercialized by SoftBank Corp. (“SoftBank”), a Japan-based telecommunications and IT operator. It enables travelers to easily search for, purchase, and activate unlimited global eSIM plans through a seamless digital experience. The first phase focuses on travelers visiting Japan as well as Japan-based travelers going abroad, leveraging SoftBank’s network for connectivity in the region. This launch represents a fully commercial market introduction, delivering immediate value to travelers while establishing a strong foundation for international
FPT Achieves HITRUST r2 v11.5.1 Certification, Demonstrating the Highest Level of Information Protection Assurance10.2.2026 04:00:00 EET | Press release
FPT, a leading global IT company, announced its in-scope platforms and facilities of FPT Data Center have earned certified status from HITRUST for cybersecurity and information protection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209729954/en/ The scope of the HITRUST r2 v11.5.1 certification includes FPT’s Application Services System, Database System, and Deployment System, all hosted and managed within the FPT Data Center in Hanoi, Vietnam, as well as the data center facility itself. The HITRUST Certification demonstrates that FPT has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that strong controls are in place to protect sensitive data and manage risk effectively. The certification also includes the HITRUST AI Security Certification, which validates that the organization’s AI systems are safeguarded against AI-specific threats such as data poisoning, model inversion, an
SheltonAI Announces Global Expansion, Senior Leadership Appointments, and Accelerated Growth10.2.2026 00:04:00 EET | Press release
SheltonAI, the institutional AI platform for valuation, announced senior executive appointments, major global expansion, and strong growth momentum entering 2026. SheltonAI announced several senior leadership appointments, including: Stephen Can, CSO, previously Executive Chairman & Founder of Blackstone Strategic Partners Peter Song, COO, previously COO of Blackstone Strategic Partners Chris Cooper, CFO, previously Global CFO at Sequoia, SoftBank, & Clearlake Capital Paige Shiring, has been promoted to Director, previously with Thoma Bravo 2026 NY Analyst Class & 10+ Hires in January SheltonAI also plans to open several regional HQs in 2026, including: New YorkSydneyGCC Region, with office lead to be announced later in Feb 2026 The company reported significant momentum entering the year, including 10+ new hires in January and over $1 trillion in incremental assets supported by the platform during the month, driven by new client deployments and expanded mandates. SheltonAI’s platform p
Xsolla to Showcase New Brand With All the Things for Developers to Go Direct-to-Consumer at DICE Summit 2026, Empowering Developers to Launch, Grow, and Win9.2.2026 23:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in the DICE (Design, Innovate, Communicate, Entertain) Summit 2026, taking place February 10-12 at the ARIA Resort & Casino in Las Vegas. As the industry's premier gathering of creative minds and thought leaders dedicated to community building and advancing interactive entertainment, DICE Summit provides the ideal venue for Xsolla to collaborate and showcase how its comprehensive platform delivers everything developers need to power video game commerce and build successful direct-to-consumer businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209768772/en/ (Graphic: Xsolla) DICE Summit brings together industry leaders, innovative developers, and creative visionaries to explore new approaches to game development and artistic expression. Xsolla's presence at the event underscore
Xsolla Brings Mobile-First Monetization Expertise to Gamesforum Barcelona 2026, Where Europe's Mobile Gaming Leaders Gather to Solve the Industry's Toughest Growth Challenges9.2.2026 21:30:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in Gamesforum Barcelona 2026, taking place Feb.10-11 at the InterContinental Hotel in Barcelona. This event brings together Europe's sharpest minds in mobile gaming for practical, data-driven sessions focused on what actually works in today's hypercompetitive mobile landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209301026/en/ (Graphic: Xsolla) With over 600 professionals from Europe's top publishers, ad networks, and studios in attendance, Gamesforum Barcelona has earned its reputation as the place where mobile gaming's most pressing problems get solved: How do you scale profitably? How do you retain players in saturated markets? How do you monetize without alienating your audience? "Gamesforum Barcelona represents everything we value about the European mobile gaming commu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom